MetaCap

Lisata Therapeutics (LSTA) vs SciSparc (SPRC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lisata Therapeutics is the larger company by market cap ($647,451 vs $481,603), about 1.3 times the size, while SciSparc is growing revenue faster (-54.6% vs -83.0%). SciSparc converts more of its revenue into profit, with a net margin of -481.2% versus -9756.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LSTA-23.17%SPRC-95.79%
+15%-43%-101%
Oct 7, 20261 yearNov 20, 2026
LSTA-15.20%SPRC-95.63%
+20%-41%-101%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LSTA versus SPRC key metrics
MetricLSTASPRC
Share price$0.8989$0.1955
Market cap$647.45K$481.60K
1-day change-1.22%-34.83%
YTD return-51.67%—
1-year return-54.14%—
5-year return-93.89%—
P/E ratio (TTM)—0.00
EPS (TTM)$-28.20$248.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$170.00K$1.31M
Revenue growth (YoY)-83.00%-54.64%
Net income (latest FY)$-16.59M$-6.28M
Gross margin—38.74%
Operating margin-10711.18%-560.18%
Net margin-9756.47%-481.16%
52-week high$76.05$29.88
52-week low$0.85$0.167
Distance from 52-week high-98.82%-99.35%
Analyst consensusnone—
Average volume13.46K2.93M
Shares outstanding720.27K2.46M
Employees213
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SciSparc is more profitable, keeping -481.2 cents of every revenue dollar as net income versus -9756.5 cents for Lisata Therapeutics.
  • SciSparc grew revenue faster in its latest fiscal year (-54.64% vs -83.00%).

About Lisata Therapeutics

LSTA stock →

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About SciSparc

SPRC stock →

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

LSTA vs SPRC FAQ

Which is bigger, Lisata Therapeutics or SciSparc?

Lisata Therapeutics (LSTA) is larger, with a market capitalization of $647.45K compared with $481.60K for SciSparc (SPRC).

Are Lisata Therapeutics and SciSparc in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons